Engineered immune cells take on tough blood cancers
NCT ID NCT05679895
First seen Mar 13, 2026 · Last updated Apr 26, 2026 · Updated 6 times
Summary
This early-stage trial tests a new treatment called CD1a-CAR T cells for people with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, modifying them to recognize and attack cancer cells, and giving them back. The study will enroll about 20 participants to check safety and see if the therapy can shrink or eliminate the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Clínic
RECRUITINGBarcelona, Spain
Contact
-
Hospital Sant Joan de Déu
RECRUITINGBarcelona, Spain
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.